File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer

TitlePatient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Authors
Keywordsdurvalumab
patient-reported outcomes
programmed cell death ligand-1
Issue Date2021
Citation
Future Oncology, 2021, v. 17, n. 10, p. 1165-1184 How to Cite?
AbstractAim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy.
Persistent Identifierhttp://hdl.handle.net/10722/326503
ISSN
2023 Impact Factor: 3.0
2023 SCImago Journal Rankings: 1.029
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorGarassino, Marina C.-
dc.contributor.authorPaz-Ares, Luis-
dc.contributor.authorHui, Rina-
dc.contributor.authorFaivre-Finn, Corinne-
dc.contributor.authorSpira, Alex-
dc.contributor.authorPlanchard, David-
dc.contributor.authorÖzgüroǧlu, Mustafa-
dc.contributor.authorDaniel, Davey-
dc.contributor.authorVicente, David-
dc.contributor.authorMurakami, Shuji-
dc.contributor.authorLanger, Corey-
dc.contributor.authorSenan, Suresh-
dc.contributor.authorSpigel, David-
dc.contributor.authorRydén, Anna-
dc.contributor.authorZhang, Yiduo-
dc.contributor.authorO'brien, Cathy-
dc.contributor.authorDennis, Phillip A.-
dc.contributor.authorAntonia, Scott J.-
dc.date.accessioned2023-03-10T02:19:44Z-
dc.date.available2023-03-10T02:19:44Z-
dc.date.issued2021-
dc.identifier.citationFuture Oncology, 2021, v. 17, n. 10, p. 1165-1184-
dc.identifier.issn1479-6694-
dc.identifier.urihttp://hdl.handle.net/10722/326503-
dc.description.abstractAim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo after CRT in patients with unresectable, stage III non-small-cell lung cancer. If available, pre-CRT tumor tissue was tested for PD-L1 tumor-cell expression, scored at prespecified (25%) and post-hoc (1%) cut-offs. PROs were assessed using EORTC QLQ C30/-LC13. Results: Similar to the intent-to-treat (ITT) population, most PROs remained stable over time across PD-L1 and CRT subgroups, with few clinically relevant differences between treatment arms. Time to deterioration was generally similar to the ITT population. Conclusion: Neither PD-L1 expression nor prior CRT-related variables influenced PROs with durvalumab therapy.-
dc.languageeng-
dc.relation.ispartofFuture Oncology-
dc.subjectdurvalumab-
dc.subjectpatient-reported outcomes-
dc.subjectprogrammed cell death ligand-1-
dc.titlePatient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2217/fon-2020-1102-
dc.identifier.pmid33583206-
dc.identifier.scopuseid_2-s2.0-85102068848-
dc.identifier.volume17-
dc.identifier.issue10-
dc.identifier.spage1165-
dc.identifier.epage1184-
dc.identifier.eissn1744-8301-
dc.identifier.isiWOS:000617913300001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats